Difference between revisions of "POEMS syndrome"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "|Phase II" to "|Phase 2")
m
Line 36: Line 36:
 
====Targeted therapy====
 
====Targeted therapy====
 
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
 
*[[Lenalidomide (Revlimid)]] 25 mg PO once per day on days 1 to 21
 +
====Glucocorticoid therapy====
 
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22
 
*[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1, 8, 15, 22
  

Revision as of 00:13, 26 May 2022

Section editor
Headshot Cowan.jpg
Andrew J. Cowan, MD
University of Washington
Seattle, WA

Social-twitter-icon.png andrewcowanmd
LinkedIn

POEMS: Peripheral neuropathy, Organomegaly, Endocrinopathy, Monoclonal plasma cell disorder, and Skin changes

1 regimens on this page
1 variants on this page


Guidelines

EMN

All lines of therapy

Lenalidomide & Dexamethasone (Rd)

back to top

Rd: Revlimid (Lenalidomide) & low-dose dexamethasone

Regimen

Study Evidence
Nozza et al. 2017 Phase 2, <20 pts

Targeted therapy

Glucocorticoid therapy

Supportive medications

28-day cycle for at least 6 cycles

References

  1. Nozza A, Terenghi F, Gallia F, Adami F, Briani C, Merlini G, Giordano L, Santoro A, Nobile-Orazio E. Lenalidomide and dexamethasone in patients with POEMS syndrome: results of a prospective, open-label trial. Br J Haematol. 2017 Dec;179(5):748-755. Epub 2017 Oct 19. link to original article contains verified protocol PubMed